Here are relevant reports on : microneedle-drug-delivery-market
-
Europe Medical Tubing Market by Material (Plastics, Rubber, Specialty Polymers), Application (Bulk Disposable Tubing, Catheters & Cannulas, Drug Delivery Systems), Structure (Single Lumen, Multi Lumen, Co-Extruded, Braided), and Country - Forecast to 2030
The Europe medical tubing market is projected to grow from USD 3.64 billion in 2025 to USD 5.14 billion by 2030, at a CAGR of 7.1% during the forecast period. The key global players in the Europe medical tubing market are Freudenberg Medical (US), RAUMEDIC AG (Germany), Vygon (France), B. Braun (Germany), Saint-Gobain (France), Trelleborg Medical (Sweden), Teleflex (US), Coloplast (Denmark), Smiths Medical (US), and TE Connectivity (Ireland).
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
Pain Patch Market by Type (Opioid & Non-Opioid), By Mode of Administration (Metered Dose & Microneedle Patches) and by Therapeutic Use (Pain relief, Anaesthesia, Cough Suppression, Smoking Cessation) - Global Forecast to 2023
The global Pain Patch market is expected to reach USD 30.95 billion by 2023 from USD 24.25 billion in 2018, growing at a CAGR of 5.0%. Rising usage of opioids in non-cancer conditions and favourable reimbursement policies, increasing research and development in this field, favourable reimbursement facilities for palliative care in North American and European countries are some factors also promoting growth.
- Published: July 2026
- Price: $ 4950
- TOC Available:
-
Microfluidic Components Market by Product (Valve, Solenoid Valve, Check Valve, Nozzle, Tubing, Micropump, Microneedle, Shuttle Valve), Industry (Automotive, Aerospace & Defense, Healthcare, Consumer Electronics, Oil & Gas) - Global Forecast to 2024
The global microfluidic components market is expected to grow from USD 3.3 billion in 2019 to USD 6.1 billion by 2024, at a compound annual growth rate (CAGR) of 12.7%. during the forecast period.The prominent players in the microfluidic components market are Parker Hannifin Corporation (US), IDEX Corporation (US), Fluigent SA (France), Staiger GmbH & Co. KG (Germany), SMC Corporation (Japan), Camozzi Automation Spa Società Unipersonale (Italy), Aignep s.p.a. (Italy), FIM Valvole Srl (Italy), Humphrey Products Corporation (US), The Lee Company (US), Dolomite Microfluidics (UK), Cellix Ltd. (Ireland), Elveflow (France), and Christian Bürkert GmbH & Co. KG (Germany).
- Published: May 2019
- Price: $ 4950
- TOC Available:
-
Chemoinformatics Market by Application (Chemical Analysis (Chemical Databases, Chemo Metrics, Molecular Modelling), Drug Discovery (High Throughput Screening, Lead Identification and Optimization, QSAR/QSPR), Drug Validation) - Global Forecast to 2023
Growth of the chemoinformatics market is primarily driven by innovations and advancements in the drug development process, advances in the computer technology, increased demand of personalized medicine. On the other hand, cost associated with the chemoinformatics software is one of the major factors restraining the growth of this market. Whereas emerging markets are expected to provide significant growth opportunities in this market.
- Published: July 2026
- Price: $ 4950
- TOC Available:
-
Glioblastoma Multiforme Drug Market by Therapy (Chemotherapy, Immunotherapy), Drug Class, End Use, Region (North America, Europe, Asia Pacific, and Rest of the World) – Global Forecast to 2027
The global glioblastoma multiforme drug market is projected to reach USD ~880 million by 2027 from USD 600 million in 2022, at a CAGR of 8% during the forecast period
- Published: July 2026
- Price: $ 4950
- TOC Available:
-
Life Science Analytics Market by Type (Descriptive, Prescriptive, Predictive), by Service (Analytics), Application (Drug Discovery, Trials, RWE, Access, Sales & Marketing, Drug Safety), End User (Pharma, Medical Device) & Region - Global Forecast to 2030
Global life science analytics market valued at $35.69B in 2024, reached $40.03B in 2025, and is projected to grow at a robust 11.4% CAGR, hitting $68.81B by 2030. Emerging technologies like artificial intelligence (AI), quantum computing, and cognitive computing play a vital role in transforming large volumes of raw data into actionable insights.
- Published: May 2025
- Price: $ 4950
- TOC Available:
-
Drug Screening Market by Offering [On-site Testing, Rapid Testing (Urine, Oral), Analytical (Breathalyzer, Immunoassay, Chromatography)], Sample (Blood, Urine, Hair), Drug (Cannabis, Alcohol), End User (Workplace, Law, Hospitals) - Global Forecast to 2030
The global drug screening market, valued at US$8.92 billion in 2024, stood at US$10.36 billion in 2025 and is projected to advance at a resilient CAGR of 15.5% from 2025 to 2030, culminating in a forecasted valuation of US$21.29 billion by the end of the period. The market for drug screening is being fueled by growing workplace and clinical testing programs, an increased need for opioid/polysubstance monitoring, and an increased use of rapid point-of-care technologies and advanced confirmatory testing (LC MS/MS) systems.
- Published: February 2026
- Price: $ 4950
- TOC Available:
-
Biopharmaceutical Contract Manufacturing Market by Service (Manufacturing, Fill-Finish), Type (Drug Substance, Drug Product), Scale (Clinical), Source (Mammalian), Therapy Area (Oncology), Molecule Type (mAbs, ADC, CGT, Vaccines) - Global Forecast to 2030
The global biopharmaceutical contract manufacturing market, valued at US$20.51 billion in 2024, stood at US$22.40 billion in 2025 and is projected to advance at a resilient CAGR of 8.8% from 2025 to 2030, culminating in a forecasted valuation of US$34.15 billion by the end of the period. The growth is primarily driven by the rising demand for outsourcing services and an increasing need for biologics and biosimilars. However, challenges related to intellectual property rights are anticipated to pose barriers to market growth.
- Published: July 2025
- Price: $ 4950
- TOC Available:
-
Therapeutic Drug Monitoring Market by Product (Equipments,Consumables), Technology (Immunoassays), Drug Class (Anti–Epileptic Drugs,Anti–Arrhythmic Drugs), Therapeutic Area (Oncology, Cardiology), Specimen (Blood), End user - Global Forecast to 2029
The global therapeutic drug monitoring market, valued at US$2.14 billion in 2023, stood at US$2.30 billion in 2024 and is projected to advance at a resilient CAGR of 8.4% from 2024 to 2029, culminating in a forecasted valuation of US$3.44 billion by the end of the period. This growth is brought on by a number of causes, such as the rise in chronic diseases like cancer, heart disease, epilepsy, and autoimmune conditions.
- Published: December 2024
- Price: $ 4950
- TOC Available:
-
Specimen Validity Testing Market by Product (Reagent, Controls, Assay Kits, Disposables), Type (Laboratory, POC Testing), End User (Workplace, Drug Screening, Pain Management, Drug Rehabilitation Centers) - Global Forecast to 2023
The global specimen validity testing market is projected to reach USD 1.49 Billion by 2023 from USD 1.10 Billion in 2018, at a CAGR of 6.3%. The growth of the market is primarily driven by the growth in drug screening market and increase in workplace drug testing. While the specimen validity testing market represents significant growth opportunities, market growth may be hindered due to the emergence of alternative drug screening tests. The specimen validity testing market is marked by the presence of several big and small players. Prominent players offering specimen validity testing products include Thermo Fisher Scientific (US), Sciteck, Inc. (US), American Bio Medica Corporation (ABMC), Alere [now a part of Abbott (US)], Express Diagnostics Int'l, Inc. (US), and Premier Biotech, Inc. (US). While, Laboratory Corporation of America Holdings (LabCorp) (US), Quest Diagnostics (US), Alere Toxicology (Alere) (US), ACM Global Laboratories (US), Clinical Reference Laboratory (CRL) (US), SureHire (Canada), and CannAmm (Canada) are some of the leading service providers.
- Published: May 2018
- Price: $ 4950
- TOC Available:
Records 41 to 50 of 50
